

Goat Anti-PDPN Antibody

Peptide-affinity purified goat antibody Catalog # AF1809a

Specification

Goat Anti-PDPN Antibody - Product Information

Application Primary Accession Other Accession Reactivity Predicted Host Clonality Concentration Isotype Calculated MW

WB, E <u>Q86YL7</u> <u>NP_001006626</u>, <u>10630</u> Human Dog Goat Polyclonal 100ug/200ul IgG 16698

Goat Anti-PDPN Antibody - Additional Information

Gene ID 10630

Other Names Podoplanin, Aggrus, Glycoprotein 36, Gp36, PA2.26 antigen, T1-alpha, T1A, PDPN {ECO:0000312|EMBL:AAH14668.2}

Dilution WB~~1:1000 E~~N/A

Format 0.5 mg lgG/ml in Tris saline (20mM Tris pH7.3, 150mM NaCl), 0.02% sodium azide, with 0.5% bovine serum albumin

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions Goat Anti-PDPN Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Goat Anti-PDPN Antibody - Protein Information

Name PDPN {ECO:0000312|EMBL:AAH14668.2}

Function

Mediates effects on cell migration and adhesion through its different partners. During



development plays a role in blood and lymphatic vessels separation by binding CLEC1B, triggering CLEC1B activation in platelets and leading to platelet activation and/or aggregation (PubMed:14522983, PubMed:15231832, PubMed:17222411, PubMed:17616532, PubMed:18215137). Interaction with CD9, on the contrary, attenuates platelet aggregation induced by PDPN (PubMed:18541721). Through MSN or EZR interaction promotes epithelial- mesenchymal transition (EMT) leading to ERZ phosphorylation and triggering RHOA activation leading to cell migration increase and invasiveness (PubMed:17046996, PubMed:21376833). Interaction with CD44 promotes directional cell migration in epithelial and tumor cells (PubMed:20962267). In lymph nodes (LNs), controls fibroblastic reticular cells (FRCs) adhesion to the extracellular matrix (ECM) and contraction of the actomyosin by maintaining ERM proteins (EZR; MSN and RDX) and MYL9 activation through association with unknown transmembrane proteins. Engagement of CLEC1B by PDPN promotes FRCs relaxation by blocking lateral membrane interactions leading to reduction of ERM proteins (EZR; MSN and RDX) and MYL9 activation (By similarity). Through binding with LGALS8 may participate in connection of the lymphatic endothelium to the surrounding extracellular matrix (PubMed:19268462). In keratinocytes, induces changes in cell morphology showing an elongated shape, numerous membrane protrusions, major reorganization of the actin cytoskeleton, increased motility and decreased cell adhesion (PubMed: 15515019). Controls invadopodia stability and maturation leading to efficient degradation of the extracellular matrix (ECM) in tumor cells through modulation of RHOC activity in order to activate ROCK1/ROCK2 and LIMK1/LIMK2 and inactivation of CFL1 (PubMed:25486435). Required for normal lung cell proliferation and alveolus formation at birth (By similarity). Does not function as a water channel or as a regulator of aguaporin-type water channels (PubMed:9651190). Does not have any effect on folic acid or amino acid transport (By similarity).

Cellular Location

[Podoplanin]: Membrane; Single-pass type I membrane protein

[ECO:000250|UniProtKB:Q62011]. Cell projection, lamellipodium membrane; Single-pass type I membrane protein {ECO:000250|UniProtKB:Q62011}. Cell projection, filopodium membrane; Single- pass type I membrane protein {ECO:0000250|UniProtKB:Q62011}. Cell projection, microvillus membrane; Single- pass type I membrane protein {ECO:0000250|UniProtKB:Q62011}. Cell projection, ruffle membrane; Single-pass type I membrane protein {ECO:0000250|UniProtKB:Q62011}. Cell projection, ruffle membrane; Single-pass type I membrane protein {ECO:0000250|UniProtKB:Q62011}. Membrane raft. Apical cell membrane. Basolateral cell membrane. Cell projection, invadopodium. Note=Localized to actin-rich microvilli and plasma membrane projections such as filopodia, lamellipodia and ruffles (By similarity). Association to the lipid rafts is required for PDPN-induced epithelial to mesenchymal transition (EMT) (PubMed:21376833). Colocalizes with CD9 in tetraspanin microdomains (PubMed:18541721). Localized at invadopodium adhesion rings in tumor cell. Association to the lipid rafts is essential for PDPN recruitment to invadopodia and ECM degradation (PubMed:25486435) {ECO:000250|UniProtKB:Q62011, ECO:0000269|PubMed:18541721,

ECO:0000269|PubMed:21376833, ECO:0000269|PubMed:25486435}

Tissue Location

Highly expressed in placenta, lung, skeletal muscle and brain. Weakly expressed in brain, kidney and liver. In placenta, expressed on the apical plasma membrane of endothelium. In lung, expressed in alveolar epithelium. Up-regulated in colorectal tumors and expressed in 25% of early oral squamous cell carcinomas



Goat Anti-PDPN Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- <u>Dot Blot</u>
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

Goat Anti-PDPN Antibody - Images



AF1809a (1 μ g/ml) staining of Human Cerebellum lysate (35 μ g protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

Goat Anti-PDPN Antibody - Background

This gene encodes a type-I integral membrane glycoprotein with diverse distribution in human tissues. The physiological function of this protein may be related to its mucin-type character. The homologous protein in other species has been described as a differentiation antigen and influenza-virus receptor. The specific function of this protein has not been determined but it has been proposed as a marker of lung injury. Alternatively spliced transcript variants encoding different isoforms have been identified.

Goat Anti-PDPN Antibody - References

Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility hot-spot. Johnatty SE, et al. PLoS Genet, 2010 Jul 8. PMID 20628624.

Incorporation of podoplanin into HIV released from HEK-293T cells, but not PBMC, is required for efficient binding to the attachment factor CLEC-2. Chaipan C, et al. Retrovirology, 2010 May 19. PMID 20482880.

Expression of podoplanin in human bone and bone tumors: New marker of osteogenic and chondrogenic bone tumors. Ariizumi T, et al. Pathol Int, 2010 Mar. PMID 20403045.



Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. Kreppel M, et al. Virchows Arch, 2010 May. PMID 20393745.

Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Rose JE, et al. Mol Med, 2010 Jul-Aug. PMID 20379614.